Psilocybin is emerging as a promising therapeutic agent for a wide range of psychiatric conditions, and clinical trials on psilocybin-assisted treatment are forthcoming in Scandinavian countries. However, little is known about attitudes towards this psychedelic compound among the general public in Nordic countries. This might represent a confound, and reduce the validity of research findings or the overall feasibility of conducting high-quality clinical trials.
The main objective of this study is to address the knowledge gap surrounding use and attitudes towards psilocybin in Norway.
We asked a representative sample of the Norwegian population ( N = 1,078) if they have ever tried psilocybin and if they would be willing to do so as part of medical treatment. These questions were part of a larger online survey on a variety personal preferences and attitudes, and the survey was not presented as a study on psilocybin.
Of the 1,078 respondents, 8% reported previous psilocybin use and 51% were willing to try psilocybin in medical treatment.
Psilocybin use is more common in Norway than the authors hypothesized, and the general public is relatively open to using psilocybin in a medical context. The latter is interpreted as promising with regards to the feasibility of conducting rigorous clinical trials on potential effects and side effects of psilocybin-assisted treatment in Norway.